Sumitomo Mitsui Trust Holdings, Inc. Neurocrine Biosciences Inc Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $145 Billion
- Q4 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 232,857 shares of NBIX stock, worth $35.1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
232,857
Previous 231,941
0.39%
Holding current value
$35.1 Million
Previous $26.7 Million
19.03%
% of portfolio
0.02%
Previous 0.02%
Shares
21 transactions
Others Institutions Holding NBIX
# of Institutions
636Shares Held
93.7MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.14 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.51 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$776 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$388 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$281 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...